|
MTX3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.71904762331133E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.96149779646748E-11 |
| Normal-vs-Stage2 |
3.921100E-03 |
| Normal-vs-Stage3 |
1.1426004586923E-10 |
| Normal-vs-Stage4 |
5.20230000189414E-08 |
| Stage1-vs-Stage2 |
2.465900E-02 |
| Stage1-vs-Stage3 |
1.930650E-01 |
| Stage1-vs-Stage4 |
4.623800E-01 |
| Stage2-vs-Stage3 |
5.600200E-03 |
| Stage2-vs-Stage4 |
2.546500E-02 |
| Stage3-vs-Stage4 |
8.110000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.96054283918556E-12 |
| Normal-vs-AfricanAmerican |
4.000000E-03 |
| Normal-vs-Asian |
1.35430000003378E-06 |
| Caucasian-vs-AfricanAmerican |
1.465220E-01 |
| Caucasian-vs-Asian |
5.597600E-01 |
| AfricanAmerican-vs-Asian |
3.552000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.77639960705778E-10 |
| Normal-vs-Female |
5.17620390994011E-11 |
| Male-vs-Female |
6.643600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.91790028303274E-10 |
| Normal-vs-Age(41-60Yrs) |
5.10239994699901E-09 |
| Normal-vs-Age(61-80Yrs) |
2.69359999860441E-08 |
| Normal-vs-Age(81-100Yrs) |
2.279800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.023600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.438200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.880000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.893000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.069600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.297600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.700100E-03 |
| Classical-VS-Follicular |
2.955200E-01 |
| Classical-VS-Other |
4.173200E-01 |
| Classical-VS-Normal |
1.00609964803766E-10 |
| Tall-VS-Follicular |
3.924700E-03 |
| Tall-VS-Other |
7.663400E-01 |
| Tall-VS-Normal |
9.09490038836225E-10 |
| Follicular-VS-Other |
3.151200E-01 |
| Follicular-VS-Normal |
4.13489999999683E-05 |
| Other-VS-Normal |
4.600300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.54060000312484E-08 |
| Normal-vs-N1 |
5.37610000961308E-09 |
| N0-vs-N1 |
1.331010E-01 |
|
|
